Page last updated: 2024-12-05

osthol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Osthol is a coumarin compound found in various plants, including Cnidium monnieri, Angelica sinensis, and Ruta graveolens. It exhibits a wide range of pharmacological activities, including anti-inflammatory, antioxidant, anti-cancer, and anti-microbial effects. Osthol has been shown to inhibit the production of pro-inflammatory cytokines, such as TNF-alpha and IL-6, and to reduce oxidative stress by scavenging free radicals. It is also known to induce apoptosis in cancer cells and inhibit the growth of bacteria and fungi. Osthol's pharmacological properties make it a promising candidate for the development of new drugs for the treatment of various diseases. Research on osthol focuses on understanding its mechanisms of action and its potential therapeutic applications. Studies have investigated its effects on different cellular pathways and its interactions with other molecules. The goal is to identify the specific targets of osthol and to develop safe and effective therapeutic strategies based on this compound.'

osthol: from Cnidium monnieri and Angelica pubescens (both Apiaceae); structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
AngelicagenusA plant genus of the family Apiaceae.[MeSH]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]
CnidiumgenusA plant genus of the family APIACEAE. Members contain osthol.[MeSH]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]
Angelica pubescensspecies[no description available]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]
Cnidium monnierispecies[no description available]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]

Cross-References

ID SourceID
PubMed CID10228
CHEMBL ID52229
CHEBI ID69832
SCHEMBL ID50436
MeSH IDM0135014

Synonyms (99)

Synonym
BRD-K78294846-001-03-3
7-methoxy-8-(3-methylbut-2-enyl)chromen-2-one
wln: t66 bovj io1 j2uy1&1
8-(3-methyl-2-butenyl)herniarin
osthole
7-methoxy-8-isopentenylcoumarin
NSC31868 ,
7-methoxy-8-(3-methyl-2-butenyl)-coumarin
nsc-31868
coumarin, 7-methoxy-8-(3-methyl-2-butenyl)-
ostole
ostol
DIVK1C_007042
SDCCGMLS-0066780.P001
nsc 31868
7-methoxy-8-(3-methyl-but-2-enyl)-chromen-2-one
smr000156202
MLS001048988
SPECTRUM4_001687
SPECTRUM_001542
MEGXP0_000155
OPREA1_642606
OPREA1_873803
ACON1_002155
SPECTRUM5_000334
BSPBIO_003369
inchi=1/c15h16o3/c1-10(2)4-7-12-13(17-3)8-5-11-6-9-14(16)18-15(11)12/h4-6,8-9h,7h2,1-3h
2h-1-benzopyran-2-one, 7-methoxy-8-(3-methyl-2-butenyl)-
7-methoxy-8-(3-methylbut-2-en-1-yl)-2h-chromen-2-one
MLS000574904
osthol
484-12-8
C09280
NCGC00095694-01
KBIO2_004590
KBIO2_002022
KBIOSS_002022
KBIOGR_001954
KBIO1_001986
KBIO2_007158
KBIO3_002589
SPECTRUM2_000723
SPECTRUM3_001645
SPBIO_000646
SPECPLUS_000946
SPECTRUM1504165
STK396321
bdbm50240512
AKOS000277663
chebi:69832 ,
CHEMBL52229 ,
7-methoxy-8-(3-methylpent-2-enyl)coumarin
NCGC00095694-03
NCGC00095694-02
7-methoxy-8-(3-methylbut-2-enyl)-1-benzopyran-2-one
A827530
BBL013019
HMS2267O21
CCG-40172
7-methoxy-8-(3-methyl-2-buten-1-yl)-2h-chromen-2-one
unii-xh1ti1759c
xh1ti1759c ,
hsdb 8479
FT-0601535
NCGC00095694-05
7-methoxy-8-(3-methyl-2-butenyl)-2h-1-benzopyran-2-one
osthole [inci]
7-methoxy-8-(3-methylbut-2-enyl)-2-chromenone
osthole [mi]
S2337
7-methoxy-8-(3-methyl-2-butenyl)coumarin
HY-N0054
SCHEMBL50436
MLS006011425
DS-0881
Q-100535
MBRLOUHOWLUMFF-UHFFFAOYSA-N
7-methoxy-8-(3-methyl-2-butenyl)-2h-chromen-2-one #
O0426
mfcd00076049
osthole, analytical standard
DTXSID20197507
sr-01000721624
SR-01000721624-4
AC-8041
osthole, primary pharmaceutical reference standard
HMS3656A07
osthole, european pharmacopoeia (ep) reference standard
SW219438-1
Q4338679
osthole (osthol)
a0o ,
osthole,(s)
1440642-68-1
BCP10832
gtpl10302
AMY40671
NCGC00095694-06
7-methoxy-8-(3-methyl-2-buten-1-yl)-2h-1-benzopyran-2-one

Research Excerpts

Overview

Osthole is a natural product that has an inhibitory effect on liver cancer. Its effect on the sensitivity of liver cancer to sorafenib is poorly understood. Osthole is an effective treatment for osteoporosis.

ExcerptReferenceRelevance
"Osthole is a natural product that has an inhibitory effect on liver cancer, but its effect on the sensitivity of liver cancer to sorafenib is poorly understood. "( Osthole Increases the Sensitivity of Liver Cancer to Sorafenib by Inhibiting Cholesterol Metabolism.
Fan, K; Huang, H; Xie, ML; Xie, T; Zhao, Y; Zhu, ZY, 2022
)
3.61
"Osthole is an effective treatment for osteoporosis. "( Effects of osthole on osteoporotic rats: a systematic review and meta-analysis.
Lu, JH; Wang, WY; Wu, B; Yang, XQ; Zhu, XF, 2022
)
2.55
"Osthole is a natural coumarin substance that has an inhibitory effect on hepatic cancer, but its radiosensitization effect on hepatoma cells has not been reported. "( Osthole increases the radiosensitivity of hepatoma cells by inhibiting GSK-3β/AMPK/mTOR pathway-controlled glycolysis.
Huang, H; Xie, ML; Xie, T; Xue, J, 2023
)
3.8
"Osthole (OST) is a simple coumarin derivative with pharmacological effects in many types of cancer cells. "( UPLC-Q-TOF/MS-Based Metabolomics Approach Reveals Osthole Intervention in Breast Cancer 4T1 Cells.
Deng, X; Han, L; Li, X; Shi, Z; Wu, E; Zhang, C, 2023
)
2.61
"Osthole (OST) is a coumarin derivative extracted from"( Osthole Antagonizes Microglial Activation in an NRF2-Dependent Manner.
Chang, LZ; Chang, MS; Chen, MY; Cheng, J; Chuang, TN; Hsieh, WT; Kuo, YH; Lin, WY; Liu, CH; Liu, HP; Wu, BT; Xiao, YR, 2023
)
3.07
"Osthole is a natural coumarin extracted from Cnidium spp."( Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling.
Cheng, Y; Kang, J; Zhang, L; Zhou, X, 2023
)
3.07
"Osthole is an agent isolated from Cnidium monnieri (L.) Cusson and has been used to treat several disorders. "( Osthole: A Traditional Chinese Medicine for Ocular Anti-Angiogenic Therapy.
Jiang, Q; Li, JJ; Li, XM; Lu, C; Tao, SY; Yan, B; Zhang, QY, 2020
)
3.44
"Osthole is a derivative of coumarin and extracted from Cnidium monnieri (L.) Cusson, which has been drawn more attention due to its high biological activity in various disease."( Osthole inhibits ovarian carcinoma cells through LC3-mediated autophagy and GSDME-dependent pyroptosis except for apoptosis.
Huang, W; Huang, X; Li, H; Liang, J; Wang, X; Xu, Y; Zhou, J, 2020
)
2.72
"Osthole is a plant-derived chemical compound that can inhibit the proliferation of malignant cells and provide potent anti-cancer effects in various tissues."( Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms.
Ashrafizadeh, M; Johnston, TP; Mohammadinejad, R; Sahebkar, A; Samarghandian, S; Yaribeygi, H, 2020
)
1.59
"Osthole is a bioactive derivative from coumarin with a wide range of pharmacotherapeutic effects."( Osthole stimulates bone formation, drives vascularization and retards adipogenesis to alleviate alcohol-induced osteonecrosis of the femoral head.
Chen, Y; Gao, J; Gao, Y; Huang, Y; Liu, P; Yang, Q; Yu, H; Zhang, C; Zhu, D, 2020
)
2.72
"Osthole (Ost) is a coumarin compound that strengthens hippocampal neurons and neural stem cells against Aβ oligomer-induced neurotoxicity in mice, and is a potential drug for the treatment of Alzheimer's disease (AD). "( Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer's Disease-Related Pathology in APP/PS-1 Mice.
Cheng, L; Fu, M; Ju, RJ; Kong, L; Li, HY; Li, XT; Liu, JJ; Ni, YN; Wang, YY; Wu, YT; Xiao, HH; Yang, JX; Yao, YJ, 2020
)
2.32
"Osthole is a natural coumarin found in a variety of plants and has been reported to have diverse biological functions, including antimicrobial, antiviral, immunomodulatory, and anticancer effects. "( Osthole interacts with an ER-mitochondria axis and facilitates tumor suppression in ovarian cancer.
Bae, H; Lee, JY; Lim, W; Song, G; Song, J, 2021
)
3.51
"Osthole (Ost) is a coumarin compound and a potential drug for Alzheimer's disease (AD). "( Multifunctional osthole liposomes and brain targeting functionality with potential applications in a mouse model of Alzheimer's disease.
Cheng, L; Deng, Y; Ju, RJ; Kong, L; Li, HY; Li, WY; Li, XT; Li, Y; Liang, XC; Lin, Y; Ni, YN; Shi, Y; Wu, YT; Xiao, HH; Yang, JX, 2021
)
2.41
"Osthole (OST) is a natural coumarin compound that exerts multiple pharmacologic effects. "( Osthole-Loaded Nanoemulsion Enhances Brain Target in the Treatment of Alzheimer's Disease via Intranasal Administration.
Hao, J; Hao, Q; Hou, X; Song, Y; Wang, J; Wang, X, 2021
)
3.51
"Osthole is a natural coumarin that exhibits wide biological and pharmacological activities such as neuroprotective, osteogenic, immunomodulation, antitumor, and anti-inflammatory effects. "( Potent
Chai, D; Du, J; Guan, SX; Huang, XW; Jiang, YY; Li, DD; Sun, Y; Zhang, HY, 2017
)
1.9
"Osthole (Ost) is a coumarin that has clear anti‑inflammatory properties."( Osthole attenuates pulmonary arterial hypertension in monocrotaline‑treated rats.
Li, Y; Qian, Z; Wang, Y; Yang, D; Zhu, L, 2017
)
2.62
"Osthole is a natural coumarin isolated from Umbelliferae plant monomers. "( Osthole induces apoptosis and suppresses proliferation via the PI3K/Akt pathway in intrahepatic cholangiocarcinoma.
He, W; Liu, F; Song, X; Xie, K; Zhang, X; Zhu, X, 2017
)
3.34
"Osthole is a bioactive coumarin derivative and has been reported to be able to enhance bone formation and improve fracture healing. "( Osthole Promotes Bone Fracture Healing through Activation of BMP Signaling in Chondrocytes.
Chen, D; Jin, H; Jin, X; Luo, C; Mi, M; Tong, P; Wang, P; Xu, T; Ying, J; Zhang, L; Zhang, S, 2017
)
3.34
"Osthole (Ost) is a coumarin that exhibits wide pharmacological effects in the cardiovascular system. "( Osthole attenuates right ventricular remodeling via decreased myocardial apoptosis and inflammation in monocrotaline-induced rats.
Li, L; Li, Y; Shi, F; Wang, L; Yang, D, 2018
)
3.37
"Osthole is a simple coumarin that has been found to have anticancer, anti-inflammatory, antiviral, anticoagulant, anticonvulsant and antiallergic activities. "( Combination of Osthole and Cisplatin Against Rhabdomyosarcoma TE671 Cells Yielded Additive Pharmacologic Interaction by Means of Isobolographic Analysis.
Guz, M; Hałasa, M; Jarząb, A; Polberg, K; Skalicka-Woźniak, K; Smok-Kalwat, J; Stepulak, A; Łuszczki, J, 2018
)
2.28
"Osthol is a natural coumarin isolated from Apiaceaous plants which has demonstrated several pharmacological effects, such as antineoplastic, anti-inflammatory and antioxidant properties."( Potential Anticancer Properties of Osthol: A Comprehensive Mechanistic Review.
Bazvandi, L; Bhattacharyya, P; Bishayee, A; Chow, N; Farooqi, AA; Farzaei, MH; Hosseinzadeh, L; Jafari, F; Mohammadi, Z; Nabavi, SM; Shokoohinia, Y; Yerer, MB, 2018
)
1.48
"Osthole is a compound that is extracted from She Chuang Zi, which is a type of traditional Chinese medicine."( Protective effects of osthole against inflammation induced by lipopolysaccharide in BV2 cells.
Bao, Y; Liu, F; Meng, X; Wang, F; Wang, H; Xie, G; Yang, J, 2018
)
1.52
"Osthole is a derivative of coumnarin, which has been used to treat several diseases, including osteoporosis. "( Comparative metabolites profiles of osthole in normal and osteoporosis rats using liquid chromatography quadrupole time-of-flight mass spectrometry.
Qin, L; Shou, D; Wang, N; Wang, X; Wu, R; Xin, H; Xu, P; Zhang, Q; Zhang, Y, 2018
)
2.2
"Osthole is an active compound isolated from Chinese herb Cnidium monnieri (L.) Cusson, and had been reported to possess antitumor effect. "( Osthole inhibits gastric cancer cell proliferation through regulation of PI3K/AKT.
Liu, X; Xu, X; Zhang, Y, 2018
)
3.37
"Osthole is a bioactive component reported in medicinal plants such as Angelica pubescens and Cnidium monnieri, known for analgesic activity. "( Osthole ameliorates neurogenic and inflammatory hyperalgesia by modulation of iNOS, COX-2, and inflammatory cytokines in mice.
Bhatti, R; Kesavan, A; Mannan, R; Singh, D; Singh, G; Singh, P, 2019
)
3.4
"Osthole is a natural product that has multiple bioactive functions and has been reported to exert potent immunosuppressive effects. "( Osthole improves collagen-induced arthritis in a rat model through inhibiting inflammation and cellular stress.
Hou, J; Huang, T; Liu, Z; Xu, R; Yang, M, 2018
)
3.37
"Osthole is an active constituent isolated from the fruit of Cnidium monnieri (L.) Cuss."( The in vitro and in vivo anti-inflammatory effect of osthole, the major natural coumarin from Cnidium monnieri (L.) Cuss, via the blocking of the activation of the NF-κB and MAPK/p38 pathways.
Chen, D; Fan, H; Gao, Z; Ji, K; Li, X; Liang, H; Liu, P; Liu, Y; Wang, X; Wu, J; Zhao, F, 2019
)
1.48
"Osthole is a natural coumarin compound most frequently extracted from plants of the Apiaceae family such as Cnidium monnieri (L.) Cusson, Angelica pubescens Maxin.f., and Peucedanum ostruthium (L.). "( Osthole inhibits proliferation and induces apoptosis in BV-2 microglia cells in kainic acid-induced epilepsy via modulating PI3K/AKt/mTOR signalling way.
Du, M; Li, YZ; Lu, Y; Sun, Z; Xu, HR; Zeng, CQ, 2019
)
3.4
"Osthole is an antitumor compound, which effect on Gallbladder cancer (GBC) has been not elucidated. "( Osthole inhibits the progression of human gallbladder cancer cells through JAK/STAT3 signal pathway both in vitro and in vivo.
Gao, Y; Le Zou, T; Liu, YB; Ren, T; Shao, ZY; Wang, HF; Wang, XA; Yuan, RY; Zhang, YJ, 2019
)
3.4
"Osthole is a pure compound isolated from Cnidiummonnieri (L.) Cusson seeds, which are used as a traditional Chinese medicine, and is anti-inflammatory, anti-apoptotic, and anti-fibrotic both in vitro and in vivo."( Osthole mitigates progressive IgA nephropathy by inhibiting reactive oxygen species generation and NF-κB/NLRP3 pathway.
Chang, JM; Chao, LK; Chen, A; Chen, HL; Hua, KF; Ka, SM; Kao, TY; Tsai, YJ; Yang, SM; Yang, SS, 2013
)
2.55
"Osthole is a natural compound extracted from a number of medicinal plants and has been shown to exert strong anticancer activities with low toxicity."( NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway.
Chen, MW; Chen, TJ; Li, Y; Ning, JJ; Ren, H; Yang, T; Zhang, S; Zhou, YF, 2015
)
1.47
"Osthole is an active component majorly contained in the fruit of Cnidium monnieri (L.) Cusson."( Osthole ameliorates hepatic fibrosis and inhibits hepatic stellate cell activation.
Chiu, YT; Fu, SL; Huang, YT; Liu, YW, 2015
)
2.58
"Osthole is an O-methylated coumadin, which was isolated and purified from the seeds of Cnidium monnieri (L.) Cusson. "( Osthole, a coumadin analog from Cnidium monnieri (L.) Cusson, stimulates corticosterone secretion by increasing steroidogenic enzyme expression in mouse Y1 adrenocortical tumor cells.
Fang, Z; Liu, X; Lu, W; Pan, Z; Zhang, Y, 2015
)
3.3
"Osthole is a Chinese herbal medicine which has been reported to possess various pharmacological functions, including hepatocellular protection."( Osthole inhibits the tumorigenesis of hepatocellular carcinoma cells.
Du, J; Gong, P; Jiang, GQ; Li, HM; Lin, ZK; Liu, J; Luo, HF; Ning, Z; Tan, G; Wang, ZY; Xin, Y, 2017
)
2.62
"Osthole is a coumarin derivative extracted from the fruits of Cnidium monnieri (L.) Cusson."( Osthole prevents cerebral ischemia-reperfusion injury via the Notch signaling pathway.
Fu, Q; Guan, J; Lv, T; Qu, S; Wei, X; Yuan, Y, 2017
)
2.62
"Osthole is an agent isolated from Cnidium monnieri (L.) Cusson and Angelica pubescens and has been used to treat several diseases, including metabolic syndromes. "( Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice.
Chang, CC; Chen, NQ; Chen, YC; Hung, LF; Liang, HJ; Liang, YC; Liu, DZ; Suk, FM; Wang, CK, 2009
)
3.24
"Osthole is a coumarin extracted from Cnidium monnieri (L.) Cusson. "( Mechanism of osthole inhibition of vascular Ca(v)1.2 current.
Cuong, NM; Fusi, F; Ha, le M; Saponara, S; Sgaragli, G, 2012
)
2.19
"Osthole is a natural coumarin compound isolated from Angelica pubescens Maxim., which possesses hypotensive effect."( Osthole relaxes pulmonary arteries through endothelial phosphatidylinositol 3-kinase/Akt-eNOS-NO signaling pathway in rats.
Chen, J; Feng, H; Huang, Y; Li, Y; Lu, P; Yang, L; Yao, L; Zhang, D; Zhu, D, 2013
)
2.55
"Osthole is an active ingredient and one of the major coumarin compounds that were identified in the genus Cnidium moonnieri (L.) Cussion, the fruit of which was used as traditional Chinese medicine to treat male impotence, ringworm infection and blood stasis conventionally. "( Investigation of the biotransformation of osthole by liquid chromatography/tandem mass spectrometry.
Chan, W; Li, J, 2013
)
2.1
"Osthole is a coumarin derivative present in medicinal plants."( Osthole prevents anti-Fas antibody-induced hepatitis in mice by affecting the caspase-3-mediated apoptotic pathway.
Hino, O; Kawasaki, T; Okamoto, T, 2003
)
2.48
"Osthol is a major bio-activity compound of the herb."( Antitumor effects of Osthol from Cnidium monnieri: an in vitro and in vivo study.
Chou, SY; Hsu, CS; Wang, CC; Wang, KT; Wang, MC, 2007
)
1.38
"Osthole is a coumarin compound and protects the liver from hepatitis by preventing the development of apoptosis."( Synthetic derivatives of osthole for the prevention of hepatitis.
Kobayashi, T; Okamoto, T; Yoshida, S, 2007
)
1.36
"Osthole is an active constituent isolated from the fruit of Cnidium monnieri (L.) Cusson, a Chinese herbal medicine, which has been used in clinics for many years."( Inhibitory effect of osthole on alcohol-induced fatty liver in mice.
Gu, ZL; Sun, F; Xie, ML; Xue, J; Zhu, LJ, 2009
)
1.39

Effects

Osthol (OST) has a wide range of pharmacological effects and has long been used in clinical medicine in China. Osthole has a vasorelaxant effect on isolated rat thoracic aortic rings.

Osthol has antioxidant properties, is capable of regulating adipogenesis, and inhibits KHK-C activity. Osthole has been found to restore bone mass in preclinical osteoporotic models. Osthol has been previously shown to inhibit tumor cell growth.

ExcerptReferenceRelevance
"Osthol (OST) has a wide range of pharmacological effects and has long been used in clinical medicine in China. "( Effects of osthol on activity, mRNA and protein expression of Cyp3a in rats in vivo.
Hu, X; Huang, W; Xia, CH; Xiong, YQ, 2020
)
2.39
"Osthole has a vasorelaxant effect on isolated rat thoracic aortic rings, via inhibition of both receptor-operated and voltage-dependent Ca2+ channels in arterial smooth muscle, leading to decreased Ca2+ influx, and via inhibition of nitric oxide release on arterial endothelial cells."( Vasorelaxant effect of osthole on isolated thoracic aortic rings in rats.
Cui, H; Fan, D; Huang, Y; Kong, L; Lü, C; Sun, M; Wang, Y; Zhai, H, 2019
)
2.27
"Osthole has been previously shown to inhibit tumor cell growth."( Osthole inhibits cell proliferation by regulating the TGF-β1/Smad/p38 signaling pathways in pulmonary arterial smooth muscle cells.
Fu, S; Hua, L; Li, YL; Li, YQ; Lv, JY; Wu, YT; Yang, DL; Yue, Y; Zhu, L, 2020
)
2.72
"Osthol (OST) has a wide range of pharmacological effects and has long been used in clinical medicine in China. "( Effects of osthol on activity, mRNA and protein expression of Cyp3a in rats in vivo.
Hu, X; Huang, W; Xia, CH; Xiong, YQ, 2020
)
2.39
"Osthole has a vasorelaxant effect on isolated rat thoracic aortic rings, via inhibition of both receptor-operated and voltage-dependent Ca2+ channels in arterial smooth muscle, leading to decreased Ca2+ influx, and via inhibition of nitric oxide release on arterial endothelial cells."( Vasorelaxant effect of osthole on isolated thoracic aortic rings in rats.
Cui, H; Fan, D; Huang, Y; Kong, L; Lü, C; Sun, M; Wang, Y; Zhai, H, 2019
)
2.27
"Osthole has been reported to regulate various signaling pathways, which in turn modulate several apoptosis-related proteins, cell cycle regulators, protein kinases, transcriptional factors, cytokines, and growth receptors affiliated with inflammation, proliferation and several other ailments."( Osthole: A Multifunctional Natural Compound with Potential Anticancer, Antioxidant and Anti-inflammatory Activities.
Hussain, G; Rasul, A; Riaz, A; Sarfraz, I; Sarker, SD; Selamoglu, Z; Shafiq, N; Shah, MA; Zafar, S; Zahoor, MK, 2021
)
2.79
"Osthol has antioxidant properties, is capable of regulating adipogenesis, and inhibits KHK-C activity."( Osthol Ameliorates Kidney Damage and Metabolic Syndrome Induced by a High-Fat/High-Sugar Diet.
Arellano-Buendía, AS; García-Arroyo, FE; Gonzaga-Sánchez, G; Johnson, RJ; Lanaspa, MA; Manterola-Romero, L; Muñoz-Jiménez, I; Osorio-Alonso, H; Pedraza-Chaverri, J; Roncal-Jiménez, CA; Sánchez-Lozada, LG; Tapia, E, 2021
)
2.79
"Osthole has previously been demonstrated to exhibit anticancer activities and has a low toxicity."( Protective effects of osthole against inflammation induced by lipopolysaccharide in BV2 cells.
Bao, Y; Liu, F; Meng, X; Wang, F; Wang, H; Xie, G; Yang, J, 2018
)
1.52
"Osthole has been widely reported to have pharmacological activities such as anti-cancer, anti-inflammation and anti-hyperlipidemic effects. "( Effect of osthole on advanced glycation end products-induced renal tubular hypertrophy and role of klotho in its mechanism of action.
Chuang, LY; Guh, JY; Huang, JS; Hwang, JY; Kan, WC; Yang, YL; Ye, YL, 2019
)
2.36
"Osthole has anti-inflammatory activities and offers certain intestinal protection."( The in vitro and in vivo anti-inflammatory effect of osthole, the major natural coumarin from Cnidium monnieri (L.) Cuss, via the blocking of the activation of the NF-κB and MAPK/p38 pathways.
Chen, D; Fan, H; Gao, Z; Ji, K; Li, X; Liang, H; Liu, P; Liu, Y; Wang, X; Wu, J; Zhao, F, 2019
)
1.48
"Osthole has been reported to possess a variety of pharmacological activities, such as antiinflammatory effect. "( Osthole attenuates the development of carrageenan-induced lung inflammation in rats.
Chen, N; Han, N; Hu, J; Ji, H; Li, Z; Song, X, 2014
)
3.29
"Osthole has been reported to have antitumor activities via the induction of apoptosis and inhibition of cancer cell growth and metastasis. "( p53 is a key regulator for osthole-triggered cancer pathogenesis.
Chen, DR; Huang, SM; Tsai, CF; Wang, MY; Yeh, WL, 2014
)
2.14
"Osthole has been found to restore bone mass in preclinical osteoporotic models. "( Osthole Promotes Endochondral Ossification and Accelerates Fracture Healing in Mice.
Chan, CW; Lai, YM; Leung, WN; Li, G; Zhang, Z, 2016
)
3.32

Actions

Osthole could increase the number of osteoclast in periodontium and promote bone remodeling at the early stage of treatment. Osthole failed to activate the mutant hTRPA1-S873V/T874L, a previously described binding site for the non-electrophilic TRPA1agonists menthol and carvacrol.

ExcerptReferenceRelevance
"Osthole failed to activate the mutant hTRPA1-S873V/T874L, a previously described binding site for the non-electrophilic TRPA1-agonists menthol and carvacrol."( The coumarin osthole is a non-electrophilic agonist of TRPA1.
Eberhardt, MM; Leffler, A; Pantke, S; Rudolf, D; Torres, KV, 2022
)
1.81
"Osthole can increase the radiosensitivity of hepatoma cells, and its radiosensitization mechanisms may be related to glycolytic inhibition by attenuating the GSK-3β/AMPK/mTOR pathway."( Osthole increases the radiosensitivity of hepatoma cells by inhibiting GSK-3β/AMPK/mTOR pathway-controlled glycolysis.
Huang, H; Xie, ML; Xie, T; Xue, J, 2023
)
3.07
"Osthole could increase the number of osteoclast in periodontium and promote bone remodeling at the early stage of treatment, its effect is dose-dependence during OTM."( [Effect of osthole on periodontal remodeling during orthodontic tooth movement in rats].
Su, YR; Wang, XX; Yang, F; Yuan, WX; Zhang, J; Zhang, LN, 2019
)
2.35
"Osthole could also inhibit the increased expression of COX-2 mRNA in spinal dorsal horn, which was a known downstream effect of ERK signaling pathway."( Osthole, a Coumadin Analog from Cnidium monnieri (L.) Cusson, Ameliorates Nucleus Pulposus-Induced Radicular Inflammatory Pain by Inhibiting the Activation of Extracellular Signal-Regulated Kinase in Rats.
Cao, MH; He, QL; Li, MN; Sun, LB; Wang, YM; Wei, M; Wu, HX; Xu, H, 2017
)
2.62
"Osthole can inhibit osteosarcoma cell proliferation and induced apoptosis effectively in a dose-dependent manner through downregulating the expression of BCL-2 and caspase-3 proteins levels and upregulating the expression of BAX proteins levels."( Osthole inhibits proliferation and induces apoptosis in human osteosarcoma cells.
Ding, H; Ding, Y; Hu, X; Lu, X; Ma, J, 2014
)
3.29
"Osthole could inhibit the NF-κB and TGF-β1 expressions by activation of PPARα/γ, and subsequently enhance the MMP-2/9 expressions in cultured CFs, and these effects of osthole may play the beneficial roles in the prevention and treatment of myocardial fibrosis."( Osthole regulates TGF-β1 and MMP-2/9 expressions via activation of PPARα/γ in cultured mouse cardiac fibroblasts stimulated with angiotensin II.
Chen, R; Xie, M; Xue, J, 2013
)
3.28
"Osthole could inhibit the TNF-α and IL-6 production in LPS-stimulated adipocytes, and its mechanism might be related to reduction of NF-κB expression via activation of PPARα/γ."( Osthole inhibits inflammatory cytokine release through PPARα/γ-mediated mechanisms in LPS-stimulated 3T3-L1 adipocytes.
Cui, Y; Shang, X; Wang, XL; Xie, ML; Zhang, Y; Zhao, X, 2015
)
3.3
"Osthole was able to suppress the levels of proinflammatory cytokines interleukin (IL)-1β and IL-6, as well as chemokines monocyte chemoattractant protein-1 and IL-8."( Osthole Attenuates Inflammatory Responses and Regulates the Expression of Inflammatory Mediators in HepG2 Cells Grown in Differentiated Medium from 3T3-L1 Preadipocytes.
Wu, SJ, 2015
)
2.58
"Osthole can inhibit bone resorption and raise the level of nutrition metabolism of femurs tissue."( [Inhibition of osthole for resorption of rats femur tissue in vitro].
Chen, KM; Gao, YH; Ma, XN; Ren, XM; Shi, WG; Yan, LJ; Zhou, J, 2015
)
2.21
"Osthol did not suppress IL-4-induced p38, ERK or JNK expression."( Effect of the Chinese herb extract osthol on IL-4-induced eotaxin expression in BEAS-2B cells.
Chiu, PR; Chu, YT; Hung, CH; Jong, YJ; Lee, MS; Lee, WT, 2008
)
1.34
"Osthol could increase the mRNA expression of CYP7A and decrease the mRNA expressions of SREBP-1c, SREBP-2, FAS and LDL receptor in liver in fat milk-induced fatty liver mice."( Osthol ameliorates fat milk-induced fatty liver in mice by regulation of hepatic sterol regulatory element-binding protein-1c/2-mediated target gene expression.
Du, R; Wang, HB; Xie, ML; Xue, J; Zhang, Y, 2011
)
2.53
"Osthol could increase androgen, gonadotropin and nitric oxide synthase (NOS) activity. "( [Effects of osthol on androgen level and nitric oxide synthase activity in castrate rats].
Li, A; Xie, J; Yuan, J; Zhou, F, 2004
)
2.15
"Osthole could inhibit alcohol-induced fatty liver in mice, and the mechanism might be associated with its anti-oxidation and suppression of TNF-alpha production."( Inhibitory effect of osthole on alcohol-induced fatty liver in mice.
Gu, ZL; Sun, F; Xie, ML; Xue, J; Zhu, LJ, 2009
)
2.11
"Osthol did not inhibit the release of calcium evoked by exogenous IP3 in permeabilized cells."( The coumarin osthol attenuates the binding of thyrotropin-releasing hormone in rat pituitary GH4C1 cells.
Ojala, T; Törnquist, K; Vuorela, H; Vuorela, P, 2001
)
1.4

Treatment

Osthole pre-treatment significantly attenuated renal dysfunction, renal histological changes, NF-κB activation, and the expression of TNF-α, IL-8, and IL-6 induced by I/R injury. In osthole-treated APP/PS1 transgenic mice, a significant improvement in learning and memory function was seen.

ExcerptReferenceRelevance
"Osthole treatment also promoted autophagy, but inhibition of autophagy by ATG7 knockdown or 3-MA showed no influence on osthole-induced ferroptosis."( Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling.
Cheng, Y; Kang, J; Zhang, L; Zhou, X, 2023
)
3.07
"Osthol treatment prevented the development of MS and ameliorated kidney damage by inhibiting KHK activity, preventing oxidative stress via nuclear factor erythroid 2-related factor (Nrf2) activation, and reducing renal lipotoxicity."( Osthol Ameliorates Kidney Damage and Metabolic Syndrome Induced by a High-Fat/High-Sugar Diet.
Arellano-Buendía, AS; García-Arroyo, FE; Gonzaga-Sánchez, G; Johnson, RJ; Lanaspa, MA; Manterola-Romero, L; Muñoz-Jiménez, I; Osorio-Alonso, H; Pedraza-Chaverri, J; Roncal-Jiménez, CA; Sánchez-Lozada, LG; Tapia, E, 2021
)
2.79
"Osthole treatment with significantly reversed CRF‑induced changes in serum creatinine, calcium, phosphorus and blood urea nitrogen levels in CRF rats."( Osthole protects against inflammation in a rat model of chronic kidney failure via suppression of nuclear factor-κB, transforming growth factor-β1 and activation of phosphoinositide 3-kinase/protein kinase B/nuclear factor (erythroid-derived 2)-like 2 sig
Dong, Z; Huang, T, 2017
)
2.62
"Osthole treatment significantly reduced the expression of the antiapoptotic protein Bcl-2 and increased the expression of the proapoptotic proteins Bax, Bak, BimL, BimS, and t-Bid."( Osthole induces human nasopharyngeal cancer cells apoptosis through Fas-Fas ligand and mitochondrial pathway.
Chang, DC; Chen, MK; Chuang, YC; Hsi, YT; Hsieh, MJ; Lin, CC; Lin, SH; Liu, PY; Lo, YS, 2018
)
2.64
"Osthole treatment also induced G2/M phase arrest and apoptosis of ESCC cells."( Osthole inhibits the PI3K/AKT signaling pathway via activation of PTEN and induces cell cycle arrest and apoptosis in esophageal squamous cell carcinoma.
Li, T; Li, Z; Liu, L; Liu, X; Long, F; Lv, Y; Zhan, Q; Zhu, X, 2018
)
2.64
"Osthole treatment also sensitized cervical cancer cells to irradiation, showing increased DNA damage as assessed by the Comet assay, and inhibited nuclear factor‑κB signaling."( Osthole enhances antitumor activity and irradiation sensitivity of cervical cancer cells by suppressing ATM/NF‑κB signaling.
Che, Y; Li, J; Li, Z; Wang, S; Yan, Y; Zou, K; Zou, L, 2018
)
2.64
"Osthole treatment significantly ameliorated I/R-induced renal functional and morphological injuries. "( Osthole ameliorates renal ischemia-reperfusion injury by inhibiting inflammatory response.
Lu, M; Ma, L; Ma, X; Qiu, M; Zhang, S; Zheng, Y, 2013
)
3.28
"Osthole treatment ameliorates renal I/R injury by inhibiting inflammatory responses in kidneys. "( Osthole ameliorates renal ischemia-reperfusion injury by inhibiting inflammatory response.
Lu, M; Ma, L; Ma, X; Qiu, M; Zhang, S; Zheng, Y, 2013
)
3.28
"Osthole treatment dramatically reduced the H2O2, MDA and OH levels in the lung homogenates."( Osthole improves acute lung injury in mice by up-regulating Nrf-2/thioredoxin 1.
Bao, ND; Chen, XJ; Dong, HY; Hou, SJ; Jin, FG; Li, ZC; Liu, ML; Shi, Y; Sun, RH; Wang, YX; Xu, DQ; Zhang, B, 2013
)
2.55
"Osthole treatment also increased hepatic phospho-p38 MAPK expression compared with vehicle-treated trauma-hemorrhaged rats."( Osthole attenuates hepatic injury in a rodent model of trauma-hemorrhage.
Hwang, TL; Liu, FC; Tsai, YF; Yu, HP, 2013
)
2.55
"Osthole treatment preserved mitochondrial membrane potential level, reduced reactive oxygen species production, increased adenosine triphosphate generation, and inhibited cytochrome c release in mitochondrial samples."( Osthole attenuates spinal cord ischemia-reperfusion injury through mitochondrial biogenesis-independent inhibition of mitochondrial dysfunction in rats.
Fei, Z; Feng, F; Fu, LA; Gao, DK; Li, L; Yuan, H; Zhou, YF, 2013
)
2.55
"Osthol treatment attenuated liver steatosis by decreasing de novo liver triglyceride synthesis and had nominal effects on insulin resistance and liver inflammation."( Osthol attenuates hepatic steatosis via decreased triglyceride synthesis not by insulin resistance.
Jeon, HJ; Jun, DW; Kim, EK; Lee, JS; Nam, HH; Saeed, WK, 2014
)
3.29
"Osthole treatment also significantly decreased the proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells in the spleen."( Osthole promotes anti-tumor immune responses in tumor-bearing mice with hepatocellular carcinoma.
Jiang, G; Liang, G; Liu, H; Wang, F; Wu, Y; Xu, H; Yao, F; Yu, X; Zhang, L, 2015
)
2.58
"Osthole pre-treatment significantly attenuated renal dysfunction, renal histological changes, NF-κB activation, and the expression of TNF-α, IL-8, and IL-6 induced by I/R injury, but the activation of PI3K/Akt signaling was further increased."( Osthole Preconditioning Protects Rats Against Renal Ischemia-Reperfusion Injury.
Gan, H; Sun, GY; Xie, DQ; Zhang, XG,
)
3.02
"Osthole pre-treatment protects rats against renal I/R injury by suppressing NF-κB activation, which is involved in PI3K/Akt signaling activation. "( Osthole Preconditioning Protects Rats Against Renal Ischemia-Reperfusion Injury.
Gan, H; Sun, GY; Xie, DQ; Zhang, XG,
)
3.02
"In osthole-treated APP/PS1 transgenic mice, a significant improvement in learning and memory function was seen, which was associated with a significant increase in the number of new neurons (Ki67(+)/NF-M(+)) and a decrease in apoptotic cells in the hippocampal region of the brain."( The Coumarin Derivative Osthole Stimulates Adult Neural Stem Cells, Promotes Neurogenesis in the Hippocampus, and Ameliorates Cognitive Impairment in APP/PS1 Transgenic Mice.
Hu, Y; Jiao, Y; Kong, L; Li, S; Yang, J; Yao, Y, 2015
)
1.24
"Osthole treatment reduced the number of macrophages/microglia and peripheral infiltrating of neutrophils and lowered the level of the proinflammatory cytokines interleukin-6 and tumor necrosis factor α in the lesioned cortex."( Osthole confers neuroprotection against cortical stab wound injury and attenuates secondary brain injury.
Jiao, Y; Kong, L; Song, J; Tao, Z; Xia, Y; Yang, J; Yao, Y; You, Z, 2015
)
2.58
"Osthole treatment might simultaneously decrease the sterol regulatory element binding protein-1c, diacylglycerol acyltransferase, and fatty acid synthase mRNA expressions in liver and adipose tissue, and increase the carnitine palmitoyltransferase-1A mRNA expression in liver and glucose transporter-4 mRNA expression in skeletal muscle, especially in the osthole 10 mg/kg group (p < 0.01)."( Osthole improves glucose and lipid metabolism via modulation of PPARα/γ-mediated target gene expression in liver, adipose tissue, and skeletal muscle in fatty liver rats.
Qi, ZG; Xie, ML; Zhao, X; Zhong, W, 2016
)
2.6
"Osthole treatment significantly attenuated cerebral dysfunction and histologic damage induced by I/R injury."( Neuroprotection of Osthole against Cerebral Ischemia/Reperfusion Injury through an Anti-apoptotic Pathway in Rats.
Ding, D; Li, K; Zhang, M, 2016
)
1.48
"The osthole- and ABZ-treated groups presented a significant reduction in wet weight of metacestodes, increase in the level of interleukin (IL)-4 and the percentage of eosinophils compared with the control group."( Efficacy of osthole for Echinococcus granulosus in vitro and Echinococcus multilocularis in vivo.
Gao, H; Jing, T; Luo, Y; Xin, Q; Yuan, M; Zhang, G, 2016
)
1.29
"Osthole treatment significantly reduced neurological deficit score and infarct volume by 38.5% and 33.8%, respectively, as compared with the untreated animals."( Osthole, a natural coumarin, improves neurobehavioral functions and reduces infarct volume and matrix metalloproteinase-9 activity after transient focal cerebral ischemia in rats.
Lian, Q; Liu, J; Liu, M; Liu, P; Mao, X; Pi, R; Xu, S; Ye, M; Yin, W, 2011
)
2.53
"Osthol treatment was associated with a decreased cross-sectional area of cardiomyocytes (p < 0.001)."( Reduction of rat cardiac hypertrophy by osthol is related to regulation of cardiac oxidative stress and lipid metabolism.
Gu, ZL; Xie, ML; Xue, J; Zhong, W; Zhou, F, 2012
)
1.37
"Osthole pretreatment significantly improved LPS-induced lung pathological changes, reduced lung wet/dry weight ratios and total protein in BALF."( Osthole protects lipopolysaccharide-induced acute lung injury in mice by preventing down-regulation of angiotensin-converting enzyme 2.
Chen, XJ; Dong, HY; Hui, YP; Li, ZC; Ma, SR; Shi, Y; Sun, RH; Wang, YX; Xu, DQ; Zhang, B, 2013
)
2.55
"Osthole treatment significantly attenuated renal dysfunction and histologic damage induced by I/R injury. "( Osthole ameliorates renal ischemia-reperfusion injury in rats.
Lu, M; Ma, L; Qiu, M; Wang, Y; Zhang, S; Zheng, Y, 2013
)
3.28
"Osthole treatment protects murine kidney from renal I/R injury by suppressing oxidative stress and cell apoptosis. "( Osthole ameliorates renal ischemia-reperfusion injury in rats.
Lu, M; Ma, L; Qiu, M; Wang, Y; Zhang, S; Zheng, Y, 2013
)
3.28
"Osthole pretreatment (from 1 to 30 microM) enhanced the sodium nitroprusside (0.3 microM)-induced relaxation of corpus cavernosum in a dose-dependent manner to a maximum of 3 times the pretreatment level at 30 microM osthole."( Effect of the plant-extract osthole on the relaxation of rabbit corpus cavernosum tissue in vitro.
Chen, CC; Chen, CF; Chen, J; Chiou, WF, 2000
)
1.32
"Treatment with osthole resulted in a significant, dose-dependent increase in the expression of pro-apoptotic proteins (cleaved caspase-3 and Bax) and decreased expression of anti-apoptotic proteins (Bcl-2 and survivin), which were consistent with evidence of apoptotic nuclear morphology revealed by DAPI staining."( In vitro anticancer activities of osthole against renal cell carcinoma cells.
Li, L; Li, Q; Liu, L; Mao, J; Tang, Q; Wang, Q; Wu, G; Zhang, Z; Zhao, B, 2017
)
1.07
"Pretreatment with osthole attenuated TMX-induced liver injury evidenced by dose-dependent reduction of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities."( Osthole prevents tamoxifen-induced liver injury in mice.
Cai, Y; Li, H; Sun, W; Zhang, XX; Zhou, WB, 2019
)
2.28
"Pre-treatment with osthole (50 mg/kg) attenuated the destruction of epithelial cells within the villi induced by intestinal I/R injury, and suppressed oxidative stress, neutrophil infiltration and modulated nitric oxide (NO) levels."( Protective effects of osthole, a natural derivative of coumarin, against intestinal ischemia-reperfusion injury in mice.
Bi, S; Dong, W; Liu, H; Liu, Z; Ma, T; Wang, X; Zhang, W; Zhang, Z, 2013
)
1.02
"Treatment with osthole suppressed the formation of lipid peroxidation products, enhanced the capacities of antioxidant enzymes and inhibited the expression of inflammatory cytokines following myocardial I/R injury."( Protective effects of osthole against myocardial ischemia/reperfusion injury in rats.
Bi, SH; Dong, WP; Ma, T; Pan, ZG; Wang, J; Wang, XW; Wang, XY; Yu, H; Zhang, WD, 2013
)
1.04
"Treatment with Osthole markedly inhibits glioma cell proliferation, as assessed by western blot with the PCNA antibody. "( Osthole exhibits anti-cancer property in rat glioma cells through inhibiting PI3K/Akt and MAPK signaling pathways.
Cao, Y; Ding, D; Du, G; Li, L; Song, Y; Wei, S; Zhan, H, 2013
)
2.19
"Treatment of osthole may protect murine intestinal tissue against intestinal I/R injury. "( [Effects and mechanism of osthole on intestinal ischemia-reperfusion injury in mice].
Li, FF; Li, YX; Lu, MD; Zhang, Z, 2013
)
1.06
"Treatment with osthole may protect against oxidative stress and tissue damage from intestinal ischemia-reperfusion injury."( Protective effects of osthole on intestinal ischemia-reperfusion injury in mice.
Li, YX; Pan, C; Wang, HZ; Zhang, Z, 2014
)
1.07
"Pretreatment with osthole significantly increased in GSH, and decreased the volume of infarction, NDS, edema, MDA, MPO, IL-1β and IL-8 compared with rats in the MCAO group at 24h after MCAO."( Neuroprotective effect of osthole against acute ischemic stroke on middle cerebral ischemia occlusion in rats.
Chao, X; Chen, T; Dong, W; Fei, Z; Ji, X; Jiang, X; Liu, W; Qu, Y; Zhen, H; Zhou, J, 2010
)
0.98

Toxicity

ExcerptReferenceRelevance
"The aim of this study was to determine and compare the anticonvulsant and acute adverse (neurotoxic) effects of imperatorin and osthole (two natural coumarin derivatives) with valproate (a classical antiepileptic drug) in the maximal electroshock seizure and chimney tests in mice."( Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study.
Andres-Mach, M; Cisowski, W; Czuczwar, SJ; Glensk, M; Glowniak, K; Luszczki, JJ; Wojda, E, 2009
)
0.8

Pharmacokinetics

High-performance liquid chromatographic (HPLC) method is developed for the determination of osthole in rat plasma. Non-osthole ingredients in LBSE showed some pharmacokinetic interactions with osthole and hence decreased its absorption levels. The results might be useful in clinical application of this traditional Chinese herbal medicine.

ExcerptReferenceRelevance
" It was applied to the pharmacokinetic study of osthole in rats after a dose of 10 mg kg-1 by intravenous administration."( Pharmacokinetics of osthole in rat plasma using high-performance liquid chromatography.
Chen, CC; Chen, CF; Tsai, TH; Tsai, TR, 1996
)
0.87
"To investigate the pharmacokinetics of osthole in rabbits and obtain the main pharmacokinetic parameters."( [Pharmacokinetics of osthole in rabbits].
An, F; Mu, JX; Wang, SH; Zhang, DS; Zhang, L, 2003
)
0.91
" According to the 3P87 pharmacokinetic program, the main parameters were calculated."( [Pharmacokinetics of osthole in rabbits].
An, F; Mu, JX; Wang, SH; Zhang, DS; Zhang, L, 2003
)
0.64
"A simple and sensitive high-performance liquid chromatographic (HPLC) method is developed for the determination of osthole in rat plasma and applied to a pharmacokinetic study in rats after administration of Fructus Cnidii extract."( HPLC determination and pharmacokinetics of osthole in rat plasma after oral administration of Fructus Cnidii extract.
Li, F; Li, Y; Liu, H; Meng, F; Xiong, Z, 2005
)
0.8
" The validated method has been successfully applied for pharmacokinetic studies of osthole from cerebral ischemia reperfusion rat plasma after oral administration."( Application of hollow fiber liquid phase microextraction coupled with high-performance liquid chromatography for the study of the osthole pharmacokinetics in cerebral ischemia hypoperfusion rat plasma.
Cheng, ZH; Liu, J; Qian, RJ; Wang, FQ; Zeng, P; Zhou, J, 2011
)
0.8
" All pharmacokinetic data were analyzed using 3P97 software."( Comparative study of pharmacokinetics and tissue distribution of osthole in rats after oral administration of pure osthole and Libanotis buchtormensis supercritical extract.
Chen, W; Fu, Q; He, X; Liu, J; Shi, J; Wang, XM; Yang, HP, 2013
)
0.63
" Non-osthole ingredients in LBSE showed some pharmacokinetic interactions with osthole and hence decreased its absorption levels (p<0."( Comparative study of pharmacokinetics and tissue distribution of osthole in rats after oral administration of pure osthole and Libanotis buchtormensis supercritical extract.
Chen, W; Fu, Q; He, X; Liu, J; Shi, J; Wang, XM; Yang, HP, 2013
)
1.14
"This study compares the pharmacokinetic characteristics and tissue distribution of osthole in rats after oral administration of pure osthole and LBSE; the results might be useful in clinical application of this traditional Chinese herbal medicine."( Comparative study of pharmacokinetics and tissue distribution of osthole in rats after oral administration of pure osthole and Libanotis buchtormensis supercritical extract.
Chen, W; Fu, Q; He, X; Liu, J; Shi, J; Wang, XM; Yang, HP, 2013
)
0.85
" This method was successfully applied to the pharmacokinetic study of osthole in rat after intravenous and oral administration."( A rapid and sensitive LC-MS/MS method for the determination of osthole in rat plasma: application to pharmacokinetic study.
Bi, X; Di, L; Kang, A; Shan, J; Yun, F; Zhao, X, 2013
)
0.86
" The method was successfully applied to a pharmacokinetic study of eight coumarins in rats after oral administration of radix angelicae pubescentis."( Simultaneous determination of scopoletin, psoralen, bergapten, xanthotoxin, columbianetin acetate, imperatorin, osthole and isoimperatorin in rat plasma by LC-MS/MS for pharmacokinetic studies following oral administration of Radix Angelicae Pubescentis e
Chang, YX; Deng, YR; Gao, XM; Guo, XR; He, J; Li, J; Ma, L; Zhang, BL; Zhang, L; Zhang, P; Zhang, QH, 2013
)
0.6
" The validated method was successfully applied to a comparative pharmacokinetic study of the two diterpenoids in rat plasma after intragastric administration of Kirenol, DHKA and Herba Siegesbeckiae extract."( Simultaneous quantification of Kirenol and ent-16β,17-dihydroxy-kauran-19-oic acid from Herba Siegesbeckiae in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies.
Guo, X; Huo, L; Jiang, Z; Lei, M; Wang, X, 2013
)
0.39
" The sensitive and selective method was applied to a pharmacokinetic study of icarrin, naringin and osthole in rats after oral administration of Gushudan capsule."( Simultaneous determination of icariin, naringin and osthole in rat plasma by UPLC-MS/MS and its application for pharmacokinetic study after oral administration of Gushudan capsules.
Deng, Y; Guo, X; Li, F; Li, N; Lu, Y; Xiong, Z; Zhao, L, 2015
)
0.88
" Data from in vivo pharmacokinetic studies showed that AUC and Cmax of the osthole loaded-ethosome were remarkably increasing compared with the other formulations."( Preparation of osthole-loaded nano-vesicles for skin delivery: Characterization, in vitro skin permeation and preliminary in vivo pharmacokinetic studies.
Jin, Y; Li, JX; Liu, DH; Meng, S; Shi, W; Wang, P; Zhang, C; Zhang, XW, 2016
)
1.02
" The results demonstrated that there were statistically significant differences in the pharmacokinetic parameters of osthole between osthole administration alone and co‑administration with borneol."( Different effects of (+)‑borneol and (‑)‑borneol on the pharmacokinetics of osthole in rats following oral administration.
Chen, XY; Liu, YH; Luo, DD; Su, ZR; Sun, CY; Wang, Q; Wang, XF; Zhan, JY; Zhang, ZB; Zheng, YF, 2017
)
0.89

Compound-Compound Interactions

Mice were randomly divided into 8 groups namely control group, PCV2 infected, Matrine combined with Osthole high dose treatment and Ribavirin positive control group. expression of GRP78, p-PERK,. p-eIF2α, ATF4, CHOP, cleaved caspase-3 and Bax proteins were significantly reduced. The expression of Bcl-2 was significantly increased in Matrine plus Osthole groups.

ExcerptReferenceRelevance
"To investigate the effects of platycodin D in combination with different active ingredients of Chinese herbs under different therapeutic principles on proliferation and invasion of 4T1 and MDA-MB-231 breast cancer cell lines."( [Effects of platycodin D in combination with different active ingredients of Chinese herbs on proliferation and invasion of 4T1 and MDA-MB-231 breast cancer cell lines].
Guo, BF; Han, XH; Liu, S; Ye, YY, 2012
)
0.38
"Verifying study showed that the inhibitory effects of platycodin D in combination with curcumenol or osthole on proliferation of 4T1 and MDA-MB-231 cells were better than those of platycodin D in combination with Ophiopogon total saponins and each ingredient used alone (P<0."( [Effects of platycodin D in combination with different active ingredients of Chinese herbs on proliferation and invasion of 4T1 and MDA-MB-231 breast cancer cell lines].
Guo, BF; Han, XH; Liu, S; Ye, YY, 2012
)
0.59
" Therefore, the aim of our study was to investigate the effect of simple coumarins (osthole, umbelliferone, esculin, and 4-hydroxycoumarin) combined with sorafenib (specific inhibitor of Raf (Rapidly Accelerated Fibrosarcoma) kinase) in programmed death induction in human glioblastoma multiforme (T98G) and anaplastic astrocytoma (MOGGCCM) cells lines."( Antiglioma Potential of Coumarins Combined with Sorafenib.
Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Zając, A, 2020
)
0.78
" KM mice were randomly divided into 8 groups namely control group, PCV2 infected, Matrine combined with Osthole high dose treatment (40 mg/kg + 12 mg/kg), medium dose treatment (20 mg/kg + 6 mg/kg), low dose treatment (10 mg/kg + 3 mg/kg), Matrine treatment (40 mg/kg), Osthole treatment (12 mg/kg) and Ribavirin positive control (40 mg/kg) groups."( Matrine combined with Osthole inhibited the PERK apoptosis of splenic lymphocytes in PCV2-infected mice model.
Fan, K; Guo, J; Khan, A; Li, H; Sun, N; Sun, P; Sun, Y; Wan, S; Xu, Y; Yin, W; Zheng, X, 2023
)
1.44
" The expression of GRP78, p-PERK, p-eIF2α, ATF4, CHOP, cleaved caspase-3 and Bax proteins were significantly reduced, while that of Bcl-2 was significantly increased in Matrine combined with Osthole groups, which alleviated the pathological changes caused by PCV2, such as interstitial pneumonia, loss of spleen lymphocytes, infiltration of macrophages and eosinophils."( Matrine combined with Osthole inhibited the PERK apoptosis of splenic lymphocytes in PCV2-infected mice model.
Fan, K; Guo, J; Khan, A; Li, H; Sun, N; Sun, P; Sun, Y; Wan, S; Xu, Y; Yin, W; Zheng, X, 2023
)
1.41

Bioavailability

Osthole, a type of coumarin derivative, owns many biological functions, but the poor water solubility and low bioavailability limit its usage in food and pharmaceutical fields. The aim of this study was to investigate the potential of solid dispersion to improve the dissolution rate and bioavailability of osthole.

ExcerptReferenceRelevance
" The results demonstrated that the absorption rate constants (Ka) or apparent permeability coefficients (Papp) of columbianetin acetate, osthole and columbianadin from extract I had no significant difference among concentration ranges of 62-555 microg x mL(-1), 101-887 microg x mL(-1), 19-186 microg x mL(-1), respectively."( [In situ rats single pass perfusion intestinal absorption of the effectivein components in Radix Angelicae Pubescentis].
Luan, LB; Wu, YN, 2008
)
0.55
" In conclusion, a likely cause of poor osthol bioavailability is rapid phase I metabolism via the cytochrome P450 pathways."( Determination of osthol and its metabolites in a phase I reaction system and the Caco-2 cell model by HPLC-UV and LC-MS/MS.
Hu, M; Wang, K; Xu, H; Yuan, Z; Zhao, Z, 2009
)
0.96
" Even though OST plays an important role in the BSYZ its bioavailability is poor."( Bioavailability enhancement of osthole after oral administration of Bushen Yizhi prescription extract to rats followed by Cnidium monnieri (L.) Cusson fruits extract in comparison to pure osthole at different doses.
Chang, X; Chen, Y; Liu, C; Liu, S; Su, R; Wang, Q; Xu, M; Yan, R; Yang, C; Yu, X; Zeng, W; Zhang, L; Zhang, S, 2014
)
0.69
"This present study indicated that the bioavailability of pure OST after oral administration was extremely low and it was dramatically enhanced because of the synergistic effect of the traditional Chinese Bushen Yizhi prescription."( Bioavailability enhancement of osthole after oral administration of Bushen Yizhi prescription extract to rats followed by Cnidium monnieri (L.) Cusson fruits extract in comparison to pure osthole at different doses.
Chang, X; Chen, Y; Liu, C; Liu, S; Su, R; Wang, Q; Xu, M; Yan, R; Yang, C; Yu, X; Zeng, W; Zhang, L; Zhang, S, 2014
)
0.69
"The aim of this study was to investigate the potential of solid dispersion to improve the dissolution rate and bioavailability of osthole (Ost), a coumarin derivative with various pharmacological activities but with poor aqueous solubility."( Preparation of osthole-polymer solid dispersions by hot-melt extrusion for dissolution and bioavailability enhancement.
Bi, X; Di, L; Kang, A; Li, J; Shan, J; Yun, F; Zhao, X, 2014
)
0.96
" As the Ost concentration-time curve showed, Ost-S100-NP can increase the plasma concentration and relative bioavailability of Ost compared with Ost-suspension by oral administration."( Antifungal activity of osthol in vitro and enhancement in vivo through Eudragit S100 nanocarriers.
Cao, YB; Gu, LQ; Han, B; Jiang, YY; Li, LP; Shen, CY; Wang, XJ; Yang, QL; Yu, YQ; Zhang, JY; Zhang, LL, 2018
)
0.79
"The study was performed aiming to enhance the solubility and oral bioavailability of poorly water-soluble drug osthole by formulating solid self-microemulsifying drug delivery system (S-SMEDDS) via spherical crystallization technique."( Preparation and Pharmacokinetics Evaluation of Solid Self-Microemulsifying Drug Delivery System (S-SMEDDS) of Osthole.
Chen, J; Fang, W; Gao, S; Gui, Y; Guo, Y; Hu, R; Lu, W; Nie, X; Shen, Q; Sun, C; Wang, B, 2018
)
0.9
"Osthole, a type of coumarin derivative, owns many biological functions, but the poor water solubility and low bioavailability limit its usage in food and pharmaceutical fields."( New insights into the binding mechanism between osthole and β-lactoglobulin: Spectroscopic, chemometrics and docking studies.
Gong, D; Hu, X; Liu, Y; Pan, J; Wang, R; Zhang, G, 2019
)
2.21
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In this study, a kind of transferrin-modified Ost liposomes (Tf-Ost-Lip) was constructed, which could improve the bioavailability and enhance brain targeting."( Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer's Disease-Related Pathology in APP/PS-1 Mice.
Cheng, L; Fu, M; Ju, RJ; Kong, L; Li, HY; Li, XT; Liu, JJ; Ni, YN; Wang, YY; Wu, YT; Xiao, HH; Yang, JX; Yao, YJ, 2020
)
0.88
" In conclusion, this study indicates that the bioavailability of OST was improved by using the OST-NE via the nasal route."( Osthole-Loaded Nanoemulsion Enhances Brain Target in the Treatment of Alzheimer's Disease via Intranasal Administration.
Hao, J; Hao, Q; Hou, X; Song, Y; Wang, J; Wang, X, 2021
)
2.06
" During the application of TCM, the researches about bioavailability enhancement of the bioactive constituents in formula are flourishing."( Screening and verification of CYP3A4 inhibitors from Bushen-Yizhi formula to enhance the bioavailability of osthole in rat plasma.
Chen, JM; Fang, JS; Huang, MJ; Li, WR; Liang, Y; Lin, MJ; Liu, JM; Ma, CR; Wang, Q; Wu, FC; Yu, WQ; Zuo, X, 2022
)
0.93
"The aim of this study is to explore the material basis and molecular mechanism from BSYZ in the bioavailability enhancement of OST."( Screening and verification of CYP3A4 inhibitors from Bushen-Yizhi formula to enhance the bioavailability of osthole in rat plasma.
Chen, JM; Fang, JS; Huang, MJ; Li, WR; Liang, Y; Lin, MJ; Liu, JM; Ma, CR; Wang, Q; Wu, FC; Yu, WQ; Zuo, X, 2022
)
0.93
"Schisantherin B, a profoundly effective CYP3A4 inhibitor screened from BSYZ antagonized the metabolism of CYP3A4 on OST via activity inhibition, therefore significantly enhanced the bioavailability of OST in rat plasma."( Screening and verification of CYP3A4 inhibitors from Bushen-Yizhi formula to enhance the bioavailability of osthole in rat plasma.
Chen, JM; Fang, JS; Huang, MJ; Li, WR; Liang, Y; Lin, MJ; Liu, JM; Ma, CR; Wang, Q; Wu, FC; Yu, WQ; Zuo, X, 2022
)
0.93

Dosage Studied

The compounds produced a clear-cut antielectroshock action in mice. osthole treatment improved the mice survival rates in the middle and high dosage groups, compared with the untreated LPS group.

ExcerptRelevanceReference
" Both of them inhibited the contraction of the left atrium and reversed the frequency-contraction response from positive to negative staircase in the higher dosage (500 and 1 mumol."( Effects of osthole on isolated guinea pig heart atria.
Li, L; Yang, L; Zhang, CL; Zhao, DK; Zhao, GS; Zhuang, FE, 1995
)
0.68
" The evaluation of time-course and dose-response relationships for imperatorin, osthole and valproate in the maximal electroshock seizure test revealed that the compounds produced a clear-cut antielectroshock action in mice and the experimentally derived ED(50) values for imperatorin ranged between 167 and 290 mg/kg, those for osthole ranged from 253 to 639 mg/kg, whereas the ED(50) values for valproate ranged from 189 to 255 mg/kg."( Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study.
Andres-Mach, M; Cisowski, W; Czuczwar, SJ; Glensk, M; Glowniak, K; Luszczki, JJ; Wojda, E, 2009
)
0.82
" Our results showed that osthole treatment improved the mice survival rates in the middle and high dosage groups, compared with the untreated LPS group."( Osthole improves acute lung injury in mice by up-regulating Nrf-2/thioredoxin 1.
Bao, ND; Chen, XJ; Dong, HY; Hou, SJ; Jin, FG; Li, ZC; Liu, ML; Shi, Y; Sun, RH; Wang, YX; Xu, DQ; Zhang, B, 2013
)
2.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
coumarins
botanical anti-fungal agentHeteroorganic entities that are plant metabolites which have significant antifungal properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency44.66845.623417.292931.6228AID485281
glp-1 receptor, partialHomo sapiens (human)Potency1.77830.01846.806014.1254AID624417
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency36.42610.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency17.28090.001310.157742.8575AID1259252; AID1259253; AID1259255
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
glucocerebrosidaseHomo sapiens (human)Potency22.01630.01268.156944.6684AID2101
chromobox protein homolog 1Homo sapiens (human)Potency63.09570.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency50.11873.981146.7448112.2020AID720708
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Exportin-1Homo sapiens (human)IC50 (µMol)1.60000.00100.58401.6000AID484914
Glyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)IC50 (µMol)208.93006.00007.33338.0000AID75720
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)52.50000.00032.177410.0000AID1501905
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)36.20000.00011.68479.3200AID400125
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)200.00000.00021.557410.0000AID400126
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)81.10000.00010.995010.0000AID1501906
Beta-secretase 1Homo sapiens (human)IC50 (µMol)500.00000.00061.619410.0000AID637774
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)EC50 (µMol)14.00000.00112.000910.0000AID1551065
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)EC50 (µMol)14.00000.00141.957810.0000AID1551065
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)EC50 (µMol)14.00000.00141.776810.0000AID1551065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (155)

Processvia Protein(s)Taxonomy
protein export from nucleusExportin-1Homo sapiens (human)
ribosomal subunit export from nucleusExportin-1Homo sapiens (human)
ribosomal large subunit export from nucleusExportin-1Homo sapiens (human)
ribosomal small subunit export from nucleusExportin-1Homo sapiens (human)
mRNA export from nucleusExportin-1Homo sapiens (human)
protein export from nucleusExportin-1Homo sapiens (human)
nucleocytoplasmic transportExportin-1Homo sapiens (human)
regulation of centrosome duplicationExportin-1Homo sapiens (human)
regulation of proteasomal ubiquitin-dependent protein catabolic processExportin-1Homo sapiens (human)
protein localization to nucleusExportin-1Homo sapiens (human)
ribosome biogenesisExportin-1Homo sapiens (human)
regulation of protein export from nucleusExportin-1Homo sapiens (human)
microtubule cytoskeleton organizationGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
positive regulation of cytokine productionGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
glucose metabolic processGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
glycolytic processGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
negative regulation of endopeptidase activityGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
regulation of macroautophagyGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
negative regulation of translationGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
killing of cells of another organismGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
positive regulation of type I interferon productionGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
peptidyl-cysteine S-trans-nitrosylationGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
protein stabilizationGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
defense response to fungusGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
neuron apoptotic processGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
killing by host of symbiont cellsGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
cellular response to type II interferonGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
RNA bindingExportin-1Homo sapiens (human)
nuclear export signal receptor activityExportin-1Homo sapiens (human)
protein bindingExportin-1Homo sapiens (human)
small GTPase bindingExportin-1Homo sapiens (human)
glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activityGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
protein bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
microtubule bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
aspartic-type endopeptidase inhibitor activityGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
peptidyl-cysteine S-nitrosylase activityGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
identical protein bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
NADP bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
NAD bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
disordered domain specific bindingGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (62)

Processvia Protein(s)Taxonomy
kinetochoreExportin-1Homo sapiens (human)
nuclear envelopeExportin-1Homo sapiens (human)
annulate lamellaeExportin-1Homo sapiens (human)
nucleoplasmExportin-1Homo sapiens (human)
nucleolusExportin-1Homo sapiens (human)
cytoplasmExportin-1Homo sapiens (human)
cytosolExportin-1Homo sapiens (human)
Cajal bodyExportin-1Homo sapiens (human)
membraneExportin-1Homo sapiens (human)
nuclear membraneExportin-1Homo sapiens (human)
intracellular membrane-bounded organelleExportin-1Homo sapiens (human)
protein-containing complexExportin-1Homo sapiens (human)
ribonucleoprotein complexExportin-1Homo sapiens (human)
nucleusExportin-1Homo sapiens (human)
cytoplasmExportin-1Homo sapiens (human)
nucleusGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
cytoplasmGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
lipid dropletGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
cytosolGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
plasma membraneGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
microtubule cytoskeletonGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
membraneGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
nuclear membraneGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
vesicleGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
intracellular membrane-bounded organelleGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
perinuclear region of cytoplasmGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
extracellular exosomeGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
GAIT complexGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
ribonucleoprotein complexGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
cytosolGlyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (119)

Assay IDTitleYearJournalArticle
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID357622Antiplatelet activity against washed rabbit platelet assessed as inhibition of collagen-induced platelet aggregation at 100 ug/mL pre-incubated 3 mins before collagen challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID1185489Cytotoxicity against human A431 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Click chemistry inspired synthesis and bioevaluation of novel triazolyl derivatives of osthol as potent cytotoxic agents.
AID1185488Cytotoxicity against human PC3 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Click chemistry inspired synthesis and bioevaluation of novel triazolyl derivatives of osthol as potent cytotoxic agents.
AID666150Inhibition of PA endonuclease at 10 uM2011PloS one, , Volume: 6, Issue:5
Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts.
AID357617Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation at 100 ug/mL pre-incubated 3 mins before arachidonic acid challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID400126Inhibition of COX11998Journal of natural products, Mar, Volume: 61, Issue:3
5-Lipoxygenase and cyclooxygenase-1 inhibitory active compounds from Atractylodes lancea.
AID334659Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID1185483Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Click chemistry inspired synthesis and bioevaluation of novel triazolyl derivatives of osthol as potent cytotoxic agents.
AID334653Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID1204915Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Anti-inflammatory coumarin and benzocoumarin derivatives from Murraya alata.
AID357627Antiplatelet activity against washed rabbit platelet assessed as inhibition of platelet activating factor-induced platelet aggregation at 20 ug/mL pre-incubated 3 mins before PAF challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID637774Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID334656Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID334661Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 300 ug/plate after 72 hrs
AID484913Inhibition of CRM1-mediated hemagglutininin-tagged HIV1 Rev protein nuclear export in human HeLa cells assessed as nuclear localization at 5 uM after 12 hrs by indirect fluorescent antibody technique2010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
Prenylcoumarin with Rev-export inhibitory activity from Cnidii Monnieris Fructus.
AID474864Antiinflammatory activity in human BEAS2B cells assessed as reduction in IL4 and TNF-alpha-induced eotaxin production at 25 uM after 48 hrs by ELISA treated 2 hrs before IL4 challenge (RVb=435.7 pg/ml)2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Homoisoflavonoid derivatives from the roots of Ophiopogon japonicus and their in vitro anti-inflammation activity.
AID334650Toxicity in Salmonella Typhimurium T98 at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1503774Cytotoxicity against human HL cells assessed as cell viability at 50 uM after 72 hrs by resazurin dye based fluorescence assay relative to control2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID334657Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID334654Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID357619Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation at 20 ug/mL pre-incubated 3 mins before arachidonic acid challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID334652Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID611884Antiproliferative activity against serum-stimulated primary rat aortic VSMC at 30 uM after 30 mins by resazurin conversion assay2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation.
AID334662Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 150 ug/plate after 72 hrs
AID1185484Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Click chemistry inspired synthesis and bioevaluation of novel triazolyl derivatives of osthol as potent cytotoxic agents.
AID611883Antiproliferative activity against rat A102011Journal of natural products, Jun-24, Volume: 74, Issue:6
Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1501905Inhibition of ovine COX1 using arachidonic acid as substrate pretreated for 3 mins followed by substrate addition measured immediately2017Journal of natural products, 09-22, Volume: 80, Issue:9
Lipid Peroxidation and Cyclooxygenase Enzyme Inhibitory Compounds from Prangos haussknechtii.
AID1700034Neuroprotective activity against oxygen-glucose deprivation-induced toxicity in human SH-SY5Y cells assessed as increase in cell viability at 10 uM by MTT assay2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
AID357614Antiplatelet activity against washed rabbit platelet assessed as inhibition of thrombin-induced platelet aggregation at 100 ug/mL pre-incubated 3 mins before thrombin challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID464030Antiinflammatory activity in human BEAS2B cells assessed as inhibition of IL4-induced eotaxin production at 10 uM after 48 hrs by ELISA pretreated for 2 hrs before IL4 challenge (Rvb = 58.5+/-4.7 ng/mL)2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Dammarane-type glycosides from Gynostemma pentaphyllum and their effects on IL-4-induced eotaxin expression in human bronchial epithelial cells.
AID539170Anticancer activity against human MDA-MB-231 assessed as inhibition of cell growth by MTT assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Discovery of novel osthole derivatives as potential anti-breast cancer treatment.
AID357623Antiplatelet activity against washed rabbit platelet assessed as inhibition of collagen-induced platelet aggregation at 50 ug/mL pre-incubated 3 mins before collagen challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID464032Antiinflammatory activity in human BEAS2B cells assessed as inhibition of IL4 and TNF-alpha-induced eotaxin production at 10 uM after 48 hrs by ELISA pretreated for 2 hrs before IL4 and TNFalpha challenge2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Dammarane-type glycosides from Gynostemma pentaphyllum and their effects on IL-4-induced eotaxin expression in human bronchial epithelial cells.
AID1700035Neuroprotection against H202-induced toxicity in human SH-SY5Y cells assessed as cytoprotection by MTT assay2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
AID334655Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID1551064Positive allosteric modulation of human GABA-A alpha1beta2gamma2S receptor expressed in Xenopus laevis oocytes assessed as increase in GABA-induced chloride channel current at 100 uM by two-electrode voltage clamp method relative to control2019European journal of medicinal chemistry, Jun-01, Volume: 171GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators.
AID1411730Inhibition of recombinant human CYP1A1 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 7-ethoxyresorufin substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID666151Inhibition of PA endonuclease at 1 uM2011PloS one, , Volume: 6, Issue:5
Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts.
AID334651Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID1185486Cytotoxicity against human NCI-H322 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Click chemistry inspired synthesis and bioevaluation of novel triazolyl derivatives of osthol as potent cytotoxic agents.
AID1551065Positive allosteric modulation of human GABA-A alpha1beta2gamma2S receptor expressed in Xenopus laevis oocytes assessed as increase in GABA-induced chloride channel current by two-electrode voltage clamp method relative to control2019European journal of medicinal chemistry, Jun-01, Volume: 171GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators.
AID1700038Neuroprotective activity against human SH-SY5Y cells assessed as Abeta42-induced cytotoxicity at 1 uM by MTT assay2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
AID539169Anticancer activity against human MCF7 assessed as inhibition of cell growth by MTT assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Discovery of novel osthole derivatives as potential anti-breast cancer treatment.
AID357626Antiplatelet activity against washed rabbit platelet assessed as inhibition of platelet activating factor-induced platelet aggregation at 50 ug/mL preincubated 3 mins before PAF challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID1189706Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID1185485Cytotoxicity against human T47D cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Click chemistry inspired synthesis and bioevaluation of novel triazolyl derivatives of osthol as potent cytotoxic agents.
AID357625Antiplatelet activity against washed rabbit platelet assessed as inhibition of platelet activating factor-induced platelet aggregation at 100 ug/mL pre-incubated 3 mins before PAF challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID1185487Cytotoxicity against human A549 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Click chemistry inspired synthesis and bioevaluation of novel triazolyl derivatives of osthol as potent cytotoxic agents.
AID1700036Neuroprotection against oxygen-glucose deprivation-induced toxicity in human SH-SY5Y cells assessed as cytoprotection by MTT assay2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
AID1501904Antioxidant activity assessed as inhibition of ferrous chloride-induced lipid peroxidation in DHA-PA labelled SLPC large unilamellar vesicle measured over 21 mins by fluorescence assay2017Journal of natural products, 09-22, Volume: 80, Issue:9
Lipid Peroxidation and Cyclooxygenase Enzyme Inhibitory Compounds from Prangos haussknechtii.
AID1091220Insecticidal activity against Bactrocera oleae exposed to 0.45 ug/cm2 compound for 12 hr assessed as insect mortality measured 72 hr post dose by petri dish exposure bioassay (Rvb = 2 +/- 2%)2008Journal of agricultural and food chemistry, Jul-23, Volume: 56, Issue:14
Isolation and identification of insecticidal components from Citrus aurantium fruit peel extract.
AID474203Antiinflammatory activity in human BEAS2B cells assessed as reduction in of IL4-induced eotaxin production at 10 uM after 48 hrs by ELISA treated 2 hrs before IL4 challenge (RVb= 60.5 pg/ml)2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Homoisoflavonoid derivatives from the roots of Ophiopogon japonicus and their in vitro anti-inflammation activity.
AID484914Inhibition of CRM1-mediated hemagglutininin-tagged HIV1 Rev protein nuclear export in human HeLa cells assessed as nucleus localization after 12 hrs by indirect fluorescent antibody technique2010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
Prenylcoumarin with Rev-export inhibitory activity from Cnidii Monnieris Fructus.
AID732687Antitubercular activity against Mycobacterium tuberculosis assessed as growth inhibition2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Syntheses of lipophilic chalcones and their conformationally restricted analogues as antitubercular agents.
AID400125Inhibition of 5-lipoxygenase1998Journal of natural products, Mar, Volume: 61, Issue:3
5-Lipoxygenase and cyclooxygenase-1 inhibitory active compounds from Atractylodes lancea.
AID1878036Agonist activity at Nrf2 (unknown origin) at 20 uM by dual-luciferase reporter gene assay2022Bioorganic & medicinal chemistry letters, 04-01, Volume: 61Design and synthesis of Osthole-based compounds as potential Nrf2 agonists.
AID1700040Neuroprotective activity against human SH-SY5Y cells assessed as Abeta42-induced cytotoxicity at 30 uM by MTT assay2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
AID334658Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID357624Antiplatelet activity against washed rabbit platelet assessed as inhibition of collagen-induced platelet aggregation at 20 ug/mL pre-incubated 3 mins before collagen challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID1700037Inhibition of LPS-induced NO production in mouse RAW264.7 cells assessed as NO production activity at 10 uM by Griess reagent based assay2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
AID357618Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation at 50 ug/mL preincubated 3 mins before arachidonic acid challenge by turbidimetric method2001Journal of natural products, Sep, Volume: 64, Issue:9
Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity.
AID75720Inhibitory concentration against glyceraldehyde-3-phosphate dehydrogenase was determined as log 1/IC502004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structure-activity relationships of novel inhibitors of glyceraldehyde-3-phosphate dehydrogenase.
AID1501906Inhibition of human COX2 expressed in insect cells using arachidonic acid as substrate pretreated for 3 mins followed by substrate addition measured immediately2017Journal of natural products, 09-22, Volume: 80, Issue:9
Lipid Peroxidation and Cyclooxygenase Enzyme Inhibitory Compounds from Prangos haussknechtii.
AID1551066Positive allosteric modulation of human GABA-A alpha1beta2gamma2S receptor expressed in Xenopus laevis oocytes assessed as increase in GABA-induced chloride channel current by two-electrode voltage clamp method2019European journal of medicinal chemistry, Jun-01, Volume: 171GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators.
AID637775Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate at 500 uM after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID334660Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 600 ug/plate after 72 hrs
AID1204916Cytotoxicity against mouse RAW264.7 cells assessed as cell survival at 80 uM after 24 hrs by MTT assay2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Anti-inflammatory coumarin and benzocoumarin derivatives from Murraya alata.
AID1700033Neuroprotection against H202-induced oxidative stress in human SH-SY5Y cells assessed as increase in cell viability at 10 uM by MTT assay2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (433)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (1.39)18.7374
1990's15 (3.46)18.2507
2000's57 (13.16)29.6817
2010's259 (59.82)24.3611
2020's96 (22.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.59 (24.57)
Research Supply Index6.08 (2.92)
Research Growth Index5.48 (4.65)
Search Engine Demand Index57.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.23%)5.53%
Reviews13 (2.97%)6.00%
Case Studies1 (0.23%)4.05%
Observational0 (0.00%)0.25%
Other422 (96.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]